Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 10, 2001

View Archived Issues

Active Biotech updates development programs

Exisulind may delay disease progression in prostate cancer patients

Copaxone reduces the percentage of permanent "black holes" in MS

Raven Biotechnologies delivers first MAb to ImmunoGen in ovarian cancer research collaboration

Matrix to seek E.U. approval of IntraDose by Q4 2001

Myriad Genetics uncovers potential of MPI-176716 as broad-spectrum cancer treatment

VaxGen receives further funding from NIH for HIV vaccine development

PLG microsphere formulation of human beta-amyloid(1-42) induces significant serum antibody response

Lorus and Faulding establish Virulizin distribution agreement for Latin America

Licensing agreement announced for ramoplanin

Karo Bio updates KB-002611 clinical development

Platinum complexes simultaneously targeting DNA and thioredoxin reductase

Positive data presented for OC-1016, a novel bone- and tissue-regenerating agent

Daiichi presents chemistry and pharmacology for diaminobutane AMPA receptor antagonists

3-Dimensional Pharmaceuticals to receive milestone payment for thrombin inhibitor program

Gene therapy for B-cell malignancies heading for phase II testing

Avigen's Coagulin-B gene therapy for hemophilia B trial on clinical hold

Phase II trial of Argatroban plus gpIIb/IIIa antagonists initiated in patients undergoing PCI

Fully humanized antibody for diagnosis and therapy of cancer

Rotta presents new leukotriene antagonists related to tyrosine

New nitroacridine derivatives with excellent in vivo antitumor activity

Inhibitors of PDE5 for sexual dysfunction and other disorders in development in Korea

Merck continues to identify inhibitors of protein prenyltransferases

Beta3-adrenoceptor agonists and use in urinary incontinence, obesity and diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...